A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice

Molecular Biotechnology

Volumn 56, Issue 6, 2014, Pages 487-497

  Aghababa, Haniyeh ^a   Mohabati Mobarez, Ashraf ^a   Khoramabadi, Nima ^a   Behmanesh, Mehrdad ^a   Mahdavi, Mehdi ^b   Tebianian, Majid ^c   Nejati, Mehdi ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Institute of Iran   (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Ag85B; Mycobacterium tuberculosis; Mycolyl transferase 85B; Re solubilization

Indexed keywords

ANTIGENS; CLONING; ESCHERICHIA COLI; IMMUNE SYSTEM; MAMMALS; PROTEINS; PURIFICATION; SOLUBILITY; VACCINES;

AG85B; COMPARATIVE APPROACH; IMMUNOSTIMULATING; MYCOBACTERIUM TUBERCULOSIS; MYCOLYL TRANSFERASE 85B; PURIFICATION METHOD; RE-SOLUBILIZATION; SYSTEMATIC OPTIMIZATION;

OPTIMIZATION;

AGAROSE; BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS MYCOLYL TRANSFERASE 85B; NITRILOTRIACETATE NICKEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; IMMUNOGLOBULIN G;

ARTICLE; CLONING; CONTROLLED STUDY; ENZYME PURIFICATION; ESCHERICHIA COLI; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ESCHERICHIA COLI; MUS; MYCOBACTERIUM TUBERCULOSIS;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, BACTERIAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900817380     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-013-9696-y     Document Type: Article

References (50)

1. Anderson, D. H., Harth, G., Horwitz, M. A., & Eisenberg, D. (2001). An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the M. tuberculosis 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. Journal of Molecular Biology, 307, 671-681. (Pubitemid 33027684)
2. Anonymous, (2010). WHO global tuberculosis control report 2010 Summary. Central European Journal Public Health, 18, 237.
3. Armitige, L. Y., Jagannath, C., Wanger, A. R., & Norris, S. J. (2000). Disruption of the genes encoding antigen 85A and antigen 85B of M. tuberculosis H37Rv: effect on growth in culture and in macrophages. Infection and Immunity, 68, 767-778. (Pubitemid 30056535)
4. Bivas-Benita, M., Lin, M. Y., Bal, S. M., Van Meijgaarden, K. E., Franken, K. L., Friggen, A. H., et al. (2009). Pulmonary delivery of DNA encoding M. tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine, 27, 4010-4017.
5. Brewer, T. F. (2000). Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clinical Infectious Diseases, 31(Suppl 3), S64-S67.
6. Chen, L., Xu, M., Wang, Z. Y., Chen, B. W., Du, W. X., Su, C., et al. (2010). The development and preliminary evaluation of a new M. tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunology and Medical Microbiology, 59, 42-52.
7. Chow, M. K., Amin, A. A., Fulton, K. F., Whisstock, J. C., Buckle, A. M., & Bottomley, S. P. (2006). REFOLD: an analytical database of protein refolding methods. Protein Expression and Purification, 46, 166-171. (Pubitemid 43247010)
8. Delogu, G., & Fadda, G. (2009). The quest for a new vaccine against tuberculosis. Journal of Infection in Developing Countries, 3, 5-15.
9. Dey, B., Jain, R., Khera, A., Rao, V., Dhar, N., Gupta, U. D., et al. (2009). Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol M. tuberculosis infection in guinea pigs. Vaccine, 28, 63-70.
10. Dheda, K., Schwander, S. K., Zhu, B., Van Zyl-Smit, R. N., & Zhang, Y. (2010). The immunology of tuberculosis: from bench to bedside. Respirology, 15, 433-450.
11. Dheenadhayalan, V., Shin, K. S., Chang, C. F., Chang, C. D., Wang, S. J., Mcdonough, S., et al. (2002). Cloning and characterization of the genes coding for antigen 85A, 85B and 85C of Mycobacterium avium subsp. paratuberculosis. DNA Sequence, 13, 287-294. (Pubitemid 35293845)
12. Dietrich, J., Aagaard, C., Leah, R., Olsen, A. W., Stryhn, A., Doherty, T. M., et al. (2005). Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. Journal of Immunology, 174, 6332-6339. (Pubitemid 40663826)
13. Dou, J., Tang, Q., Yu, F., Yang, H., Zhao, F., Xu, W., et al. (2010). Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model. Immunobiology, 215, 133-142.
14. D'souza, S., Rosseels, V., Romano, M., Tanghe, A., Denis, O., Jurion, F., et al. (2003). Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from M. tuberculosis . Infection and Immunity, 71, 483-493.
15. Galluccio, M., Amelio, L., Scalise, M., Pochini, L., Boles, E., & Indiveri, C. (2012). Over-expression in E. coli and purification of the humanOCTN2 transport protein. MolecularBiotechnology, 50, 1-7.
16. Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., Van Soolingen, D., et al. (2010). Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, 375, 1830-1843.
17. Giri, P. K., Verma, I., & Khuller, G. K. (2006). Enhanced immunoprotective potential of M. tuberculosis Ag85 complex protein based vaccine against airway M. tuberculosis challenge following intranasal administration. FEMS Immunology and Medical Microbiology, 47, 233-241. (Pubitemid 43881743)
18. Harth, G., Lee, B. Y., Wang, J., Clemens, D. L., & Horwitz, M. A. (1996). Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of M. tuberculosis. Infection and Immunity, 64, 3038-3047. (Pubitemid 26256143)
19. Hawkridge, T., & Mahomed, H. (2011). Prospects for a new, safer and more effective TB vaccine. Paediatric Respiratory Reviews, 12, 46-51.
20. Horwitz, M. A., Lee, B. W., Dillon, B. J., & Harth, G. (1995). Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of M. tuberculosis. Proceedings of the National Academy of Sciences USA, 92, 1530-1534.
21. Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Deck, R. R., et al. (1996). Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine, 2, 893-898. (Pubitemid 26296760)
22. Kaufmann, S. H. (2011). Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infectious Diseases, 11, 633-640.
23. Kaufmann, S. H., Hussey, G., & Lambert, P. H. (2010). New vaccines for tuberculosis. Lancet, 375, 2110-2119.
24. Kremer, L., Maughan, W. N., Wilson, R. A., Dover, L. G., & Besra, G. S. (2002). The M. tuberculosis antigen 85 complex and mycolyltransferase activity. Letters in Applied Microbiology, 34, 233-237. (Pubitemid 34415692)
25. Lakey, D. L., Voladri, R. K., Edwards, K. M., Hager, C., Samten, B., Wallis, R. S., et al. (2000). Enhanced production of recombinant M. tuberculosis antigens in E. coli by replacement of low-usage codons. Infection and Immunity, 68, 233-238. (Pubitemid 30016702)
26. Li, D. K., Bao, L., Zhang, Y., & Sun, Z. (2010). Construction and expression of recombinant Mycobacterium bovis BCG with the ompA-likemembrane protein gene Loa22 of Leptospira interrogans serovar. Sichuan Da Xue Xue Bao Yi Xue Ban, 41, 189-193.
27. Li, Q., Yu, H., Zhang, Y., Wang, B., Jiang, W., Da, Z., et al. (2011). Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against M. tuberculosis infection in mice. Scandinavian Journal of Immunology, 73, 568-576.
28. Lu, D., Garcia-Contreras, L., Muttil, P., Padilla, D., Xu, D., Liu, J., et al. (2010). Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J, 12, 338-347.
29. Luo, Y., Wang, B., Hu, L., Yu, H., Da, Z., Jiang, W., et al. (2009). Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against M. tuberculosis in mice. Vaccine, 27, 6179-6185.
30. Macedo, G. C., Bozzi, A., Weinreich, H. R., Bafica, A., Teixeira, H. C., & Oliveira, S. C. (2011). Human T cell and antibody-mediated responses to the M. tuberculosis recombinant 85A, 85B, and ESAT-6 antigens. Clinical and Developmental Immunology, 2011, 351573.
31. Matsuo, K., Yamaguchi, R., Yamazaki, A., Tasaka, H., & Yamada, T. (1988). Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen. Journal of Bacteriology, 170, 3847-3854.
32. Nurul, A. A., & Norazmi, M. N. (2010). Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum. Parasitology Research, 108, 887-897.
33. Okada, M., & Kita, Y. (2010). Tuberculosis vaccine development: the development of novel (preclinical) DNA vaccine. Human Vaccines, 6, 297-308.
34. Phan, J., Yamout, N., Schmidberger, J., Bottomley, S. P., & Buckle, A. M. (2011). Refolding your protein with a little help from REFOLD. Methods in Molecular Biology, 752, 45-57.
35. Qu, P., Ma, J. H., Zhang, X. M., Huang, X. J., Yang, X. W., & Yan-Fang, S. (2010). A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis. Indian Journal of Experimental Biology, 48, 436-443.
36. Rogl, H., Kosemund, K., Kuhlbrandt, W., & Collinson, I. (1998). Refolding of E. coli produced membrane protein inclusion bodies immobilised by nickel chelating chromatography. FEBS Letters, 432, 21-26. (Pubitemid 28360732)
37. Rouanet, C., & Locht, C. (2010). Boosting BCG to protect against TB. Expert Review of Respiratory Medicine, 4, 339-348.
38. Shi, C., Chen, L., Chen, Z., Zhang, Y., Zhou, Z., Lu, J., et al. (2010). Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine, 28, 5237-5244.
39. Shi, C. H., Xu, Z. K., Zhu, D. S., Li, Y., Bai, Y. L., & Xue, Y. (2005). Screening and construction of recombinant BCG strains expressing the Ag85B-ESAT6 fusion protein. Zhonghua Jie He He Hu Xi Za Zhi, 28, 254-257. (Pubitemid 44763471)
40. Speranza, V., Colone, A., Cicconi, R., Palmieri, G., Giovannini, D., Grassi, M., et al. (2010). Recombinant BCG-Rv1767 amount determines, in vivo, antigen-specific T cells location, frequency, and protective outcome. Microbial Pathogenesis, 48, 150-159.
41. Tanghe, A., D'souza, S., Rosseels, V., Denis, O., Ottenhoff, T. H., Dalemans, W., et al. (2001). Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infection and Immunity, 69, 3041-3047.
42. Triccas, J. A. (2011). Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioengineered Bugs, 1, 110-115.
43. Trunz, B. B., Fine, P., & Dye, C. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet, 367, 1173-1180.
44. Tsenova, L., Harbacheuski, R., Sung, N., Ellison, E., Fallows, D., & Kaplan, G. (2007). BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine, 25, 5126-5132. (Pubitemid 46907374)
45. Verreck, F. A., Vervenne, R. A., Kondova, I., Van Kralingen, K. W., Remarque, E. J., Braskamp, G., et al. (2009). MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE, 4, e5264.
46. Wang, C., Chen, Z., Fu, R., Zhang, Y., Chen, L., Huang, L., et al. (2011). A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against M. tuberculosis infection in mice. Medical Microbiology and Immunology, 200, 165-175.
47. Wang, J., Qie, Y., Zhu, B., Zhang, H., Xu, Y., Wang, Q., et al. (2009). Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of M. tuberculosis in C57BL/6 mice. Medical Microbiology and Immunology, 198, 5-11.
48. Wiker, H. G., & Harboe, M. (1992). The antigen 85 complex: a major secretion product of M. tuberculosis. Microbiological Reviews, 56, 648-661.
49. Wiker, H. G., Nagai, S., Harboe, M., & Ljungqvist, L. (1992). A family of cross-reacting proteins secreted by M. tuberculosis. Scandinavian Journal of Immunology, 36, 307-319.
50. Wu, J., Xu, J., Cai, C., Gao, X., Li, L., & Zhong, N. (2009). Ag85B DNA vaccine suppresses airway inflammation in a murine model of asthma. Respiratory Research, 10, 51.